Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Amgen Inc. | Tezepelumab - SOURCE | Oral corticosteroid dependent asthma. | Phase 3 | Subcutaneous | Respiratory | |
| Amgen Inc. | BLINCYTO - (Golden Gate) | Newly diagnosed Philadelphia chromosome-negative (Ph-) B-ALL | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Amgen Inc. | Tezepelumab | Eosinophilic esophagitis (EoE) | Phase 3 | Ongoing | Subcutaneous | Gastroenterology |
| Amgen Inc. | ABP 654 - (STELARA biosimilar) | Plaque psoriasis | Phase 3 | Ongoing | Subcutaneous | Immunology: Anti-TNF |
| Amgen Inc. | AMG 133 (maridebart cafraglutide) - (MariTide) | Obesity and without diabetes | Phase 2 | Data Released | subcutaneous | Endocrinology |
| Amgen Inc. | OTEZLA | Palmoplantar pustulosis for Japanese patients | Phase 2 | oral | Immunology | |
| Amgen Inc. | Fipaxalparant (formerly AMG 670/HZN 825) | Idiopathic pulmonary fibrosis | Phase 2 | Trial Discontinued | Oral | Respiratory |
| Amgen Inc. | Rocatinlimab (AMG 451/KHK4083) | Prurigo nodularis | Phase 3 | Enrollment Initiation | Subcutaneous | #N/A |
